Jun 28, 2026 – 5.27pmEchoIQ, a buzzy medical AI software company improving the detection of structural heart disease, is seeking to capitalise on a more than 600 per cent increase in its share price over the past year and a new deal with Pro Medicus.Echo IQ is using artificial intelligence and data to improve diagnosis of structural heart disease. Sarah Thompson has co-edited Street Talk since 2009, specialising in private equity, investment banking, M&A and equity capital markets stories. Prior to that, she spent 10 years in London as a markets and M&A reporter at Bloomberg and Dow Jones.Kanika Sood is a journalist based in Sydney who writes for the Street Talk column.Emma Rapaport is a co-editor of the Street Talk column. Prior to that, she was a markets reporter at The Australian Financial Review.Subscribe to gift this articleGift 5 articles to anyone you choose each month when you subscribe.Subscribe nowAlready a subscriber?
EchoIQ set to launch $100m raise on back of Pro Medicus deal
The buzzy medical AI software company began wall crossing investors over the weekend, Street Talk can reveal.
153 words~1 min read
